Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calcifediol for prevention and treatment of COVID-19-induced acute respiratory syndrome
2020-001717-20Phase 2Terminated
- Sponsor
- Fundación para la Investigación Biomédica de Córdoba
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of calcifediol in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS), sponsored by Fundación para la Investigación Biomédica de Córdoba. Primary endpoint: Admission to Intensive Care Unit or need for invasive mechanical ventilation or death. Started Apr 2020; status: terminated.
02
Drugs
calcifediol
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2020-001717-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001717-20.